Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Imprimis Pharmaceuticals Inc Receives Institutional Review Board (IRB) Approval For Phase III Clinical Trial Protocol


Monday, 22 Jul 2013 08:30am EDT 

Imprimis Pharmaceuticals, Inc. announced that it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor. Imprimis has engaged Agility Clinical, Inc., a Carlsbad, CA-based consulting and contract research organization (CRO), to conduct the study at 20 - 30 US sites. The IRB-approved Phase III trial is a randomized, multicenter, double-blind, parallel-group study to assess the efficacy and safety of Impracor (ketoprofen 10% cream) compared with placebo in the treatment of acute pain (flare) associated with osteoarthritis (OA) of the knee. 

Company Quote

6.15
-0.2 -3.15%
11 Jul 2014